Get startedLog in
    Picture of HANS BIOMED logo

    042520 — HANS BIOMED Income Statement

    0.000.00%
    kr flag iconLast trade - 00:00
    HealthcareAdventurousSmall CapFalling Star
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for HANS BIOMED, fiscal year end - September 30th, KRW millions except per share, conversion factor applied.

    2019
    September 30th
    2020
    September 30th
    2021
    September 30th
    2022
    September 30th
    2023
    September 30th
    Period Length:12 M12 M12 M12 M12 M
    Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue66,99180,09859,09874,45978,032
    Cost of Revenue
    Gross Profit40,14842,51529,22945,68345,123
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses56,03292,62475,44273,16682,553
    Operating Profit10,959-12,526-16,3441,293-4,521
    Gain / Loss on Sale of Assets
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes11,484-16,700-21,6173,501-23,532
    Provision for Income Taxes
    Net Income After Taxes9,511-18,171-22,1264,923-24,092
    Minority Interest
    Net Income Before Extraordinary Items
    Net Income9,951-17,840-18,2896,147-23,045
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Dilution Adjustment
    Diluted Net Income9,951-17,840-18,2892,369-23,045
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS1,152-1,207-2,053180-2,127
    Dividends per Share